---
title: "Bezuclastinib: Gastrointestinal stromal tumor"
description: "Formulary evidence on Bezuclastinib in Gastrointestinal stromal tumor. Clinical evidence covers PEAK, SARC044, INTRIGUE, A6181004, 05-177, and PLX121-01. 191 evidence topics quoted from 76 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Bezuclastinib: Gastrointestinal stromal tumor

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Bezuclastinib

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Gastrointestinal stromal tumor

<a id="topic-1.1.1-1"></a>

##### Summary

The cited U.S. epidemiology study reported an increase in annual age-adjusted incidence from 0.55 per 100,000 in 2001 to 0.78 per 100,000 in 2011. Severe fatigue occurred in 30% of participants with GIST and 33% of those receiving a TKI in the cited fatigue study. A recurrence-cost study reported an additional $4464 per patient per month in total healthcare costs for patients with recurrence.

Source: [Ma et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4294949/); [Poort et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27233141/); [Guérin et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25422992/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Bezuclastinib Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

PEAK randomized 413 participants: 204 to bezuclastinib plus sunitinib and 209 to sunitinib. Median progression-free survival by blinded independent central review was 16.5 versus 9.2 months. Objective response rates were 45.6% versus 25.8%. Grade 3 or higher ALT/AST increases were reported in 10.8% versus 1.4%. Treatment-related adverse events led to study-treatment discontinuation in 7.4% versus 3.8%. Overall-survival data remained immature in the subsequent company update.

Source: [Dana-Farber Cancer Institute (2026)](https://www.newswise.com/articles/dana-farber-researchers-to-present-two-plenary-studies-and-additional-late-breaking-cancer-research-at-2026-asco); [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de); [Cogent Biosciences GIST new drug application submission initiation announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-initiate-new-drug-application-nda-submission); [Cogent Biosciences (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-positive-results-bezuclastinib-peak); [Cogent Biosciences PEAK detailed results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-detailed-clinical-data-peak-phase-3); [Cogent Biosciences second quarter 2026 results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-11)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Bezuclastinib

No evidence found.

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

The reported PEAK results support a progression-free-survival and response-rate benefit for bezuclastinib plus sunitinib compared with sunitinib alone after prior imatinib. Overall-survival data remained immature. The application received Priority Review, and the reported target action date was November 30, 2026. The company continued to describe GIST approval as potential rather than completed.

Source: [Cogent Biosciences GIST new drug application submission initiation announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-initiate-new-drug-application-nda-submission); [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de); [Cogent Biosciences second quarter 2026 results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-11); [Cogent Biosciences GIST new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-0)

## Related pages
- [Bezuclastinib in Gastrointestinal stromal tumor: Terms and abbreviations](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/terms-and-abbreviations.md)
- [Bezuclastinib: Gastrointestinal stromal tumor](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/executive-summary.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Product information and disease description](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/product-information-and-disease-description.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Clinical evidence](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/clinical-evidence.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Economic information and modeling report](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economics) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economics.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: References](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/references) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/references.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: prevalence by geography](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/prevalence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/prevalence.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/cost-effectiveness-analyses.md)
